Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 85
- 试验地点
- 2
- 主要终点
- Reduction in the systolic and diastolic blood pressures
研究概览
简要总结
Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic subjects with decreased serum magnesium levels Design : Randomised double blind placebo controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum magnesium deficiency and uncomplicated hypertension.
Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo.
Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
- •Decreased serum magnesium levels
- •Uncomplicated hypertension
- •40 and 75 years of age
- •Men and Women
排除标准
- •Chronic diarrhea
- •Alcohol intake (equal or more than 30 g per day)
- •Use of diuretics and/or calcium antagonists drugs
- •Previous oral magnesium supplementation
- •Ischemic diseases; AND
- •Reduced renal function
结局指标
主要结局
Reduction in the systolic and diastolic blood pressures
时间窗: 2 y
次要结局
- Average increase of serum magnesium levels Changes in lipid profile(2 y)